Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
NA
Total Enrollment
15 participants
Study Classification
INTERVENTIONAL
Study Start Date
2024-03-01
Study Completion Date
2026-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of the study:
Evaluation of the clinical efficacy and safety of the use of collagen matrix/membrane in the surgical treatment of the consequences of injuries and diseases of the musculoskeletal system (anterior cruciate ligament tears, rigid first toe) by using IKDC, KOOS, ACLOAS, VAS, AOFAS, SF-36 scales
Evaluation of the clinical efficacy and safety of the use of collagen matrix/membrane in the surgical treatment of the consequences of injuries and diseases of the musculoskeletal system (anterior cruciate ligament tears, rigid first toe) by using IKDC, KOOS, ACLOAS, VAS, AOFAS, SF-36 scales
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Reconstruction of the Anterior Cruciate Ligament of the Knee Joint, by the Method of Stabilization of the Screw With a Bioabsorbable Method, With or Without the Use of Autogenous Spongiform Bone Grafts.
NCT05328544
Anterior Cruciate Ligament Injuries
Anterior Cruciate Ligament Rupture
Anterior Cruciate Ligament Tear
+2 more
UNKNOWN
NA
Development of Biomedical Technology for the Treatment of Ankle Cartilage Using Injectable Biocomposite Hydrogel
NCT06028763
Ankle Osteoarthritis
RECRUITING
NA
Clinical and Comparative Evaluation of the Treatment Results of Arthroscopic Reconstruction of Cartilage Defects in the Knee Joint With the Use of Autogenous Cartilage Graft With PRP GF (Platelet-rich Plasma With Growth Factors)
NCT05328674
Cartilage Damage
Cartilage Injury
Knee Injuries
UNKNOWN
NA
Robot-Assisted Versus Conventional Arthroscopic ACL Reconstruction: A Prospective Comparative Study
NCT07086417
Anterior Cruciate Ligament
NOT_YET_RECRUITING
NA
Intraarticular Collagen in Patients With Gonarthrosis
NCT06275880
Gonarthrosis
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Application of Collagen in Treatment of the Consequences of Injuries and Diseases of the Musculoskeletal System
Indications:
* Damage to the anterior cruciate ligament (ACL) of the knee joint
* Rigid first toe
Research centers:
University Clinical Hospital No. 1 of the First Sechenov Moscow State Medical University (Sechenov University)
The product under study:
The collagen membrane
Specifications:
-The product is a membrane made of type 1 collagen obtained from the ligaments of cattle. Chemically cross-linked with glutaraldehyde. The size of the membrane is 15x4x0.3 cm in dry form (can be adjusted depending on the patient's need).
Product shape: tape (medical device) Composition: type 1 collagen Packaging: in a sterilization bag Transportation: in a dry place, protected from light, at a temperature of 10 to 30 °C.
Shelf life: 2 years Storage: in a dry place, protected from light, at a temperature of 10 to 30 °C. Purpose: for implantation Storage conditions of the product: in a dry place, protected from light, at a temperature from 10 to 30 °C. Soak in saline solution for 10 minutes before use.
Sterilization: Steripak electron beam sterilization Manufacturer: Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Research objectives:
Tasks for the reconstruction of the ACL using a collagen membrane:
1. Change in the score of the Form for registering the results of the knee joint examination of the International Knee Documentation Committee (IKDC);
2. Change in the score of the Knee injury and Osteoarthritis Outcome Score (KOOS) relative to the baseline level;
3. Change in the score of the Modified Lysholm scale relative to the initial level;
4. Assessment of the condition of the transplant based on the results of control MRI data, measured on Anterior Cruciate Ligament OsteoArthritis Score (ACLOAS)
Tasks for the application of collagen spacer of the first metatarsophalangeal joint:
1. Formation of clinical groups of patients with 3-4 stages of Hallux rigidus.
2. The development of personalized collagen, the formation of a membrane of the required size
3. Formation of a unified protocol of the operational manual
4. Development of a program of postoperative orthopedic regimen and rehabilitation
Assessment of the formation of syndesmosis by using instrumental research methods
Safety assessment parameters:
The frequency of adverse events and serious adverse events according to subjective complaints, physical examination, vital signs, ECG (Electrocardiography) and laboratory tests against the background of treatment using the technique of collagen membrane transplantation
The study population:
For the reconstruction of the anterior cruciate ligament using a collagen membrane:
men and women from 18 to 60 years old, with partial or complete damage to the anterior cruciate ligament, who will undergo autograft surgery, will be included in the work
For the collagen spacer of the first toe:
men and women from 18 to 60 years old, with 3-4 stages of Hallux rigidus, who will undergo resection arthroplasty with the introduction of a biocompatible collagen spacer into the joint cavity, will be included in the work
Number of patients:
10 patients with ACL damage 5 patients with a rigid first toe
Duration of the study:
For each patient - 12 months.
Research methodology:
Design for the reconstruction of the ACL using a collagen membrane:
The design involves the study of the medical device in experimental treatment groups in comparison with the control group.
The study group will initially include 5 patients. As a reference group, the results of treatment of 5 patients with ACL reconstruction by autograft.
Design for the collagen spacer of the first toe:
The study group will initially include 5 patients.
Description of the work stages:
For ACL reconstruction using a collagen membrane:
Screening:
* Procedure for obtaining informed consent;
* Collection of demographic data, medical history; registration of previous surgical interventions on the knee joint;
* Assessment of vital signs (blood pressure, heart rate, respiratory rate, t°);
* Measurement of height, body weight, body mass index (BMI) (growth is estimated once per study - at screening);
* Physical examination;
* Evaluation of MRI of the knee joint (ACLOAS);
* Registration of the previous/concomitant therapy;
* Registration of pain therapy;
* Assessment of compliance with the inclusion/non-inclusion criteria;
For patients who meet the preliminary inclusion criteria and do not meet any of the criteria for non-inclusion in the screening, the date and time of arthroscopy will be assigned.
The researcher gives the patient:
* Patient information sheet and informed consent form;
* Patient's card;
* Rehabilitation program.
Hospitalization:
Day 1
* Assessment of vital signs (blood pressure, heart rate, respiratory rate, t°);
* Measurement of body weight, BMI;
* Physical examination;
* Patients will be assessed according to the following scales: the Knee injury and Osteoarthritis Outcome Score (KOOS), the International Knee Documentation Committee (IKDC), assessment on the Modified Lysholm Scale
* Assessment of compliance with the inclusion/non-inclusion criteria;
* Assessment of exclusion criteria;
Day 2 Surgical treatment: ligament reconstruction. After surgery, adverse events, concomitant therapy, pain therapy, and vital signs will be re-evaluated.
Day 3-7 (Discharge)
* Assessment of adverse events, exclusion criteria, concomitant therapy, pain therapy;
* assessment of vital signs (blood pressure, heart rate, respiratory rate, t°);
* Providing instructions on the prescribed rehabilitation program;
* discharge from the hospital.
Observation period Visit 1 (Week 2)
* Removal of postoperative sutures
* Assessment of the implementation of the prescribed rehabilitation program;
* Providing further instructions on the prescribed rehabilitation program;
* Assessment of vital signs (blood pressure, heart rate, respiratory rate, t°);
* Measurement of body weight, BMI;
* Physical examination;
Visit 2 (Week 6)
* Assessment of the implementation of the prescribed rehabilitation program;
* Providing further instructions on the rehabilitation program;
* Assessment of vital signs (blood pressure, heart rate, respiratory rate, t°);
* Physical examination;
* Assessment according to the following scales: the Knee injury and Osteoarthritis Outcome Score (KOOS), the International Knee Documentation Committee (IKDC)
* Assessment on the Modified Lysholm scale;
* MRI of the operated knee joint (ACLOAS);
* Preparation of an interim report to assess the safety of the material (for the first patient included in the study).
Visit 3 (Week 24-48)
* Assessment of the implementation of the prescribed rehabilitation program;
* Providing instructions on the prescribed rehabilitation program;
* Assessment of vital signs (blood pressure, heart rate, respiratory rate, t°);
* Measurement of body weight, BMI;
* Physical examination;
* Assessment according to the following scales: the Knee injury and Osteoarthritis Outcome Score (KOOS), the International Knee Documentation Committee (IKDC)
* Assessment on the Modified Lysholm scale;
* MRI of the operated knee joint (ACLOAS).
For the collagen spacer of the first toe
Screening:
* Procedure for obtaining informed consent;
* Collection of demographic data, medical history;
* Assessment of vital signs (blood pressure, heart rate, respiratory rate, t°);
* Measurement of height, body weight, body mass index (BMI) (growth is estimated once per study - at screening);
* Physical examination;
* Evaluation of foot radiographs in two projections, functional MSCT (Multislice spiral computed tomography) of the foot
* Registration of the previous/concomitant therapy;
* Registration of pain therapy;
* Assessment of compliance with the inclusion/non-inclusion criteria;
For patients who meet the preliminary inclusion criteria and do not meet any of the criteria for non-inclusion in the screening, the date and time of the operation will be assigned.
The researcher gives the patient:
* Patient information sheet and informed consent form;
* Patient's card;
Hospitalization:
Day 1
* Assessment of vital signs (blood pressure, heart rate, respiratory rate, t°);
* Measurement of body weight, BMI;
* Physical examination;
* Patients will be evaluated according to the scales: VAS (visual analog pain scale), AOFAS (American Orthopaedic Foot and Ankle Society, Ankle-Hindfoot Score), SF-36 (36-Item Short Form Survey)
* Assessment of compliance with the inclusion/non-inclusion criteria;
* Assessment of exclusion criteria
Day 2 Surgical treatment: resection arthroplasty of the first metatarsophalangeal joint with implantation of a collagen spacer. After the operation, adverse events will be re-evaluated, symptomatic, analgesic therapy will be performed, and vital signs will be dynamically evaluated.
* Dressing of the postoperative wound
* Performing a control radiography of the operated feet in two projections
* Learning to walk in orthopedic shoes
Day 3-7 (Discharge)
* Assessment of adverse events, symptomatic, analgesic therapy;
* assessment of vital signs (blood pressure, heart rate, respiratory rate, t°);
* Walking in orthopedic shoes under the supervision of the attending physician;
* Dressing of the postoperative wound
* discharge from the hospital.
The observation period.
1. Visit 1 (Week 2)
* Clinical examination
* Filling in evaluation scales by the patient
* Dressing of the postoperative wound, removal of stitches
* Performing a control radiography of the operated feet in two projections
* Evaluation of results (data from evaluation scales (VAS, AOFAS, SF-36), evaluation of functional and radiological results)
2. Visit 2 (Week 4)
* Clinical examination
* Filling in evaluation scales by the patient
* Performing a control radiography of the operated feet in two projections
* Evaluation of the results (data from evaluation scales (VAS, AOFAS, SF-36), assessment of pain syndrome and amplitude of back flexion in the metatarsophalangeal joint and radiological result)
3. Visit 3 (Week 8)
* Clinical examination
* Filling in evaluation scales by the patient
* Performing a control radiography of the operated feet in two projections
* Evaluation of the results (data from evaluation scales (VAS, AOFAS, SF-36), assessment of pain syndrome and amplitude of back flexion in the metatarsophalangeal joint and radiological result)
Indications:
* Damage to the anterior cruciate ligament (ACL) of the knee joint
* Rigid first toe
Research centers:
University Clinical Hospital No. 1 of the First Sechenov Moscow State Medical University (Sechenov University)
The product under study:
The collagen membrane
Specifications:
-The product is a membrane made of type 1 collagen obtained from the ligaments of cattle. Chemically cross-linked with glutaraldehyde. The size of the membrane is 15x4x0.3 cm in dry form (can be adjusted depending on the patient's need).
Product shape: tape (medical device) Composition: type 1 collagen Packaging: in a sterilization bag Transportation: in a dry place, protected from light, at a temperature of 10 to 30 °C.
Shelf life: 2 years Storage: in a dry place, protected from light, at a temperature of 10 to 30 °C. Purpose: for implantation Storage conditions of the product: in a dry place, protected from light, at a temperature from 10 to 30 °C. Soak in saline solution for 10 minutes before use.
Sterilization: Steripak electron beam sterilization Manufacturer: Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Research objectives:
Tasks for the reconstruction of the ACL using a collagen membrane:
1. Change in the score of the Form for registering the results of the knee joint examination of the International Knee Documentation Committee (IKDC);
2. Change in the score of the Knee injury and Osteoarthritis Outcome Score (KOOS) relative to the baseline level;
3. Change in the score of the Modified Lysholm scale relative to the initial level;
4. Assessment of the condition of the transplant based on the results of control MRI data, measured on Anterior Cruciate Ligament OsteoArthritis Score (ACLOAS)
Tasks for the application of collagen spacer of the first metatarsophalangeal joint:
1. Formation of clinical groups of patients with 3-4 stages of Hallux rigidus.
2. The development of personalized collagen, the formation of a membrane of the required size
3. Formation of a unified protocol of the operational manual
4. Development of a program of postoperative orthopedic regimen and rehabilitation
Assessment of the formation of syndesmosis by using instrumental research methods
Safety assessment parameters:
The frequency of adverse events and serious adverse events according to subjective complaints, physical examination, vital signs, ECG (Electrocardiography) and laboratory tests against the background of treatment using the technique of collagen membrane transplantation
The study population:
For the reconstruction of the anterior cruciate ligament using a collagen membrane:
men and women from 18 to 60 years old, with partial or complete damage to the anterior cruciate ligament, who will undergo autograft surgery, will be included in the work
For the collagen spacer of the first toe:
men and women from 18 to 60 years old, with 3-4 stages of Hallux rigidus, who will undergo resection arthroplasty with the introduction of a biocompatible collagen spacer into the joint cavity, will be included in the work
Number of patients:
10 patients with ACL damage 5 patients with a rigid first toe
Duration of the study:
For each patient - 12 months.
Research methodology:
Design for the reconstruction of the ACL using a collagen membrane:
The design involves the study of the medical device in experimental treatment groups in comparison with the control group.
The study group will initially include 5 patients. As a reference group, the results of treatment of 5 patients with ACL reconstruction by autograft.
Design for the collagen spacer of the first toe:
The study group will initially include 5 patients.
Description of the work stages:
For ACL reconstruction using a collagen membrane:
Screening:
* Procedure for obtaining informed consent;
* Collection of demographic data, medical history; registration of previous surgical interventions on the knee joint;
* Assessment of vital signs (blood pressure, heart rate, respiratory rate, t°);
* Measurement of height, body weight, body mass index (BMI) (growth is estimated once per study - at screening);
* Physical examination;
* Evaluation of MRI of the knee joint (ACLOAS);
* Registration of the previous/concomitant therapy;
* Registration of pain therapy;
* Assessment of compliance with the inclusion/non-inclusion criteria;
For patients who meet the preliminary inclusion criteria and do not meet any of the criteria for non-inclusion in the screening, the date and time of arthroscopy will be assigned.
The researcher gives the patient:
* Patient information sheet and informed consent form;
* Patient's card;
* Rehabilitation program.
Hospitalization:
Day 1
* Assessment of vital signs (blood pressure, heart rate, respiratory rate, t°);
* Measurement of body weight, BMI;
* Physical examination;
* Patients will be assessed according to the following scales: the Knee injury and Osteoarthritis Outcome Score (KOOS), the International Knee Documentation Committee (IKDC), assessment on the Modified Lysholm Scale
* Assessment of compliance with the inclusion/non-inclusion criteria;
* Assessment of exclusion criteria;
Day 2 Surgical treatment: ligament reconstruction. After surgery, adverse events, concomitant therapy, pain therapy, and vital signs will be re-evaluated.
Day 3-7 (Discharge)
* Assessment of adverse events, exclusion criteria, concomitant therapy, pain therapy;
* assessment of vital signs (blood pressure, heart rate, respiratory rate, t°);
* Providing instructions on the prescribed rehabilitation program;
* discharge from the hospital.
Observation period Visit 1 (Week 2)
* Removal of postoperative sutures
* Assessment of the implementation of the prescribed rehabilitation program;
* Providing further instructions on the prescribed rehabilitation program;
* Assessment of vital signs (blood pressure, heart rate, respiratory rate, t°);
* Measurement of body weight, BMI;
* Physical examination;
Visit 2 (Week 6)
* Assessment of the implementation of the prescribed rehabilitation program;
* Providing further instructions on the rehabilitation program;
* Assessment of vital signs (blood pressure, heart rate, respiratory rate, t°);
* Physical examination;
* Assessment according to the following scales: the Knee injury and Osteoarthritis Outcome Score (KOOS), the International Knee Documentation Committee (IKDC)
* Assessment on the Modified Lysholm scale;
* MRI of the operated knee joint (ACLOAS);
* Preparation of an interim report to assess the safety of the material (for the first patient included in the study).
Visit 3 (Week 24-48)
* Assessment of the implementation of the prescribed rehabilitation program;
* Providing instructions on the prescribed rehabilitation program;
* Assessment of vital signs (blood pressure, heart rate, respiratory rate, t°);
* Measurement of body weight, BMI;
* Physical examination;
* Assessment according to the following scales: the Knee injury and Osteoarthritis Outcome Score (KOOS), the International Knee Documentation Committee (IKDC)
* Assessment on the Modified Lysholm scale;
* MRI of the operated knee joint (ACLOAS).
For the collagen spacer of the first toe
Screening:
* Procedure for obtaining informed consent;
* Collection of demographic data, medical history;
* Assessment of vital signs (blood pressure, heart rate, respiratory rate, t°);
* Measurement of height, body weight, body mass index (BMI) (growth is estimated once per study - at screening);
* Physical examination;
* Evaluation of foot radiographs in two projections, functional MSCT (Multislice spiral computed tomography) of the foot
* Registration of the previous/concomitant therapy;
* Registration of pain therapy;
* Assessment of compliance with the inclusion/non-inclusion criteria;
For patients who meet the preliminary inclusion criteria and do not meet any of the criteria for non-inclusion in the screening, the date and time of the operation will be assigned.
The researcher gives the patient:
* Patient information sheet and informed consent form;
* Patient's card;
Hospitalization:
Day 1
* Assessment of vital signs (blood pressure, heart rate, respiratory rate, t°);
* Measurement of body weight, BMI;
* Physical examination;
* Patients will be evaluated according to the scales: VAS (visual analog pain scale), AOFAS (American Orthopaedic Foot and Ankle Society, Ankle-Hindfoot Score), SF-36 (36-Item Short Form Survey)
* Assessment of compliance with the inclusion/non-inclusion criteria;
* Assessment of exclusion criteria
Day 2 Surgical treatment: resection arthroplasty of the first metatarsophalangeal joint with implantation of a collagen spacer. After the operation, adverse events will be re-evaluated, symptomatic, analgesic therapy will be performed, and vital signs will be dynamically evaluated.
* Dressing of the postoperative wound
* Performing a control radiography of the operated feet in two projections
* Learning to walk in orthopedic shoes
Day 3-7 (Discharge)
* Assessment of adverse events, symptomatic, analgesic therapy;
* assessment of vital signs (blood pressure, heart rate, respiratory rate, t°);
* Walking in orthopedic shoes under the supervision of the attending physician;
* Dressing of the postoperative wound
* discharge from the hospital.
The observation period.
1. Visit 1 (Week 2)
* Clinical examination
* Filling in evaluation scales by the patient
* Dressing of the postoperative wound, removal of stitches
* Performing a control radiography of the operated feet in two projections
* Evaluation of results (data from evaluation scales (VAS, AOFAS, SF-36), evaluation of functional and radiological results)
2. Visit 2 (Week 4)
* Clinical examination
* Filling in evaluation scales by the patient
* Performing a control radiography of the operated feet in two projections
* Evaluation of the results (data from evaluation scales (VAS, AOFAS, SF-36), assessment of pain syndrome and amplitude of back flexion in the metatarsophalangeal joint and radiological result)
3. Visit 3 (Week 8)
* Clinical examination
* Filling in evaluation scales by the patient
* Performing a control radiography of the operated feet in two projections
* Evaluation of the results (data from evaluation scales (VAS, AOFAS, SF-36), assessment of pain syndrome and amplitude of back flexion in the metatarsophalangeal joint and radiological result)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Anterior Cruciate Ligament Injuries
Hallux Rigidus
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
PARALLEL
Main group for ACL: 5 patients with ACL injury, who undergo ACL reconstruction with collagen membrane augmentation; Reference group for ACL: 5 patients with ACL injury, who undergo ACL reconstruction without collagen membrane augmentation; Main group for HR (Hallux Rigidus): 5 patients with Hallux Rigidus, who undergo resection arthroplasty with introduction of collagen membrane Reference group: none
Primary Study Purpose
TREATMENT
Blinding Strategy
DOUBLE
Participants
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
The 1st group
ACL reconstruction + collagen membrane
Group Type
OTHER
Anterior cruciate ligament reconstruction, using graft, augmented with collagen membrane
Intervention Type
PROCEDURE
Wrapping graft (tendon of the long fibular muscle) with collagen membrane before implantation
The 2nd group
ACL reconstruction (control)
Group Type
OTHER
Anterior cruciate ligament reconstruction, using graft, not augmented with collagen membrane (control group)
Intervention Type
PROCEDURE
Implantation of the native graft (tendon of the long fibular muscle) without any augmentation method
The 3rd group
Hallux Rigidus + collagen membrane
Group Type
OTHER
Resection arthroplasty of the first metatarsophalangeal joint with the introduction of a collagen membrane into the joint cavity
Intervention Type
PROCEDURE
Arthroplasty with consequent collagen membrane implantation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anterior cruciate ligament reconstruction, using graft, augmented with collagen membrane
Wrapping graft (tendon of the long fibular muscle) with collagen membrane before implantation
Intervention Type
PROCEDURE
Anterior cruciate ligament reconstruction, using graft, not augmented with collagen membrane (control group)
Implantation of the native graft (tendon of the long fibular muscle) without any augmentation method
Intervention Type
PROCEDURE
Resection arthroplasty of the first metatarsophalangeal joint with the introduction of a collagen membrane into the joint cavity
Arthroplasty with consequent collagen membrane implantation
Intervention Type
PROCEDURE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
For ACL reconstruction groups:
* Type of damage (rupture of the anterior cruciate ligament (complete or partial);
* Availability of an informed consent form signed and dated by the patient.
* The patient's understanding of the strict requirements of the protocol, rehabilitation program and follow-up program and the desire to follow them.
* The patient's consent to the use of the following drugs: nonsteroidal anti-inflammatory drugs (NSAIDs) (according to indications); antibiotics; anticoagulants.
For collagen membrane of the first toe:
* The type of degenerative disease of the first metatarsophalangeal joint is Hallux rigidus of stage 3-4.
* Availability of an informed consent form signed and dated by the patient.
* The patient's understanding of the strict requirements of the protocol, rehabilitation program and follow-up program and the desire to follow them.
* The patient's consent to the use of the following drugs: nonsteroidal anti-inflammatory drugs (NSAIDs) (according to indications); antibiotics; anticoagulants
* Abuse of alcohol or narcotic substances (medicines).
* Any clinically significant or symptomatic vascular or neurological disease of the lower extremities.
* The presence of rheumatoid arthritis, parainfectious or infectious arthritis and the condition after the listed diseases, as well as the following diseases in the area of the damaged knee joint: septic arthritis, inflammatory joint disease, recurrent pseudopodagra, Paget's disease, ochronosis, acromegaly, hemochromatosis, Wilson-Konovalov disease, primary osteochondromatosis, hereditary diseases, mutation of collagen genes.
* Pregnancy and planned pregnancy (inability to perform MRI), lactation period.
* Obesity (body mass index \> 30 kg/m2).
* Uncontrolled diabetes mellitus.
* Significant cardiovascular diseases currently or within 12 months prior to screening, including: chronic heart failure of class III or IV (according to the classification of the New York Cardiological Association), severe arrhythmia requiring treatment with antiarrhythmic drugs of classes Ia, Ib, Ic or III, unstable angina pectoris, myocardial infarction, heart and coronary surgery blood vessels, significant diseases of the heart valves, uncontrolled arterial hypertension with systolic blood pressure \> 180 mmHg and diastolic blood pressure \> 110 mmHg, pulmonary embolism or deep vein thrombosis;
* Significant thyroid dysfunction in the decompensation stage;
* Any uncontrolled concomitant somatic disease, including through a stable therapy regimen;
* Nephrotic syndrome, moderate to severe chronic renal failure, or significant kidney disease with creatinine levels \> 1.5 mg/dl (132 mmol/l) in men and \> 1.4 mg/dl (123 mmol/l) in women or glomerular filtration rate (GFR) \< 60 ml/min;
* Current diagnosis of osteomyelitis and (or) infection with human immunodeficiency virus (HIV-1, HIV-2) and (or) hepatitis C virus (HCV) and (or) hepatitis B virus (HBV) and (or) syphilis. An increase in AST (aspartate transaminase), ALT (alanine transaminase) or alkaline phosphatase of serum ≥ 2.5 times from the upper limit of the norm; an increase in the level of total bilirubin ≥ 2 times from the upper limit of the norm;
* Significant protocol violations that may affect patient safety and/or the integrity of the study data (in consultation with the medical monitor).
* Type of damage (rupture of the anterior cruciate ligament (complete or partial);
* Availability of an informed consent form signed and dated by the patient.
* The patient's understanding of the strict requirements of the protocol, rehabilitation program and follow-up program and the desire to follow them.
* The patient's consent to the use of the following drugs: nonsteroidal anti-inflammatory drugs (NSAIDs) (according to indications); antibiotics; anticoagulants.
For collagen membrane of the first toe:
* The type of degenerative disease of the first metatarsophalangeal joint is Hallux rigidus of stage 3-4.
* Availability of an informed consent form signed and dated by the patient.
* The patient's understanding of the strict requirements of the protocol, rehabilitation program and follow-up program and the desire to follow them.
* The patient's consent to the use of the following drugs: nonsteroidal anti-inflammatory drugs (NSAIDs) (according to indications); antibiotics; anticoagulants
* Abuse of alcohol or narcotic substances (medicines).
* Any clinically significant or symptomatic vascular or neurological disease of the lower extremities.
* The presence of rheumatoid arthritis, parainfectious or infectious arthritis and the condition after the listed diseases, as well as the following diseases in the area of the damaged knee joint: septic arthritis, inflammatory joint disease, recurrent pseudopodagra, Paget's disease, ochronosis, acromegaly, hemochromatosis, Wilson-Konovalov disease, primary osteochondromatosis, hereditary diseases, mutation of collagen genes.
* Pregnancy and planned pregnancy (inability to perform MRI), lactation period.
* Obesity (body mass index \> 30 kg/m2).
* Uncontrolled diabetes mellitus.
* Significant cardiovascular diseases currently or within 12 months prior to screening, including: chronic heart failure of class III or IV (according to the classification of the New York Cardiological Association), severe arrhythmia requiring treatment with antiarrhythmic drugs of classes Ia, Ib, Ic or III, unstable angina pectoris, myocardial infarction, heart and coronary surgery blood vessels, significant diseases of the heart valves, uncontrolled arterial hypertension with systolic blood pressure \> 180 mmHg and diastolic blood pressure \> 110 mmHg, pulmonary embolism or deep vein thrombosis;
* Significant thyroid dysfunction in the decompensation stage;
* Any uncontrolled concomitant somatic disease, including through a stable therapy regimen;
* Nephrotic syndrome, moderate to severe chronic renal failure, or significant kidney disease with creatinine levels \> 1.5 mg/dl (132 mmol/l) in men and \> 1.4 mg/dl (123 mmol/l) in women or glomerular filtration rate (GFR) \< 60 ml/min;
* Current diagnosis of osteomyelitis and (or) infection with human immunodeficiency virus (HIV-1, HIV-2) and (or) hepatitis C virus (HCV) and (or) hepatitis B virus (HBV) and (or) syphilis. An increase in AST (aspartate transaminase), ALT (alanine transaminase) or alkaline phosphatase of serum ≥ 2.5 times from the upper limit of the norm; an increase in the level of total bilirubin ≥ 2 times from the upper limit of the norm;
* Significant protocol violations that may affect patient safety and/or the integrity of the study data (in consultation with the medical monitor).
Exclusion Criteria
* The patient's refusal to participate in the study;
* The development of an allergic reaction to the product;
* Loss of contact with the patient for further observation;
* The decision of the research physician to terminate the patient's participation in the study prematurely if, in the opinion of the researcher, the patient cannot continue further participation in the study for any reason.
* The development of an allergic reaction to the product;
* Loss of contact with the patient for further observation;
* The decision of the research physician to terminate the patient's participation in the study prematurely if, in the opinion of the researcher, the patient cannot continue further participation in the study for any reason.
Minimum Eligible Age
18 Years
Maximum Eligible Age
60 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
I.M. Sechenov First Moscow State Medical University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alexey V Lychagin, MD, PhD
Role: STUDY_CHAIR
IM Sechenov University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
university clinical hospital № 1I.M.Sechenov First Moscow State Medical University. The Department of Traumatology, Orthopedics and Disaster Surgery
Moscow, , Russia
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Russia
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0403
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study of Collagen Scaffold for the Repair of Elbow Cartilage Injury
NCT07149896
NOT_YET_RECRUITING
PHASE3
A Study to Evaluate the Incrediwear Products Immediately After ACL Repair
NCT06668376
ENROLLING_BY_INVITATION
NA
A Comparison of Outcomes After Anterior Cruciate Ligament (ACL) or Anterior Cruciate Ligament and Meniscus (ACL+Meniscus) Surgery Using Semiconductor Fabric Products
NCT06979804
RECRUITING
NA
Arthroscopic Autologous Chondrocyte Implantation Versus Microfractures
NCT01947374
COMPLETED
PHASE3
Evaluation of Clinical and Radiographic Outcomes of Meniscal Lesion Treatment Using Collagen Scaffolds (CMI)
NCT06597357
COMPLETED
A Study to Compare Two Techniques for Articular Cartilage Repair:ACIC Vs. MCIC
NCT01984450
UNKNOWN
NA
Comparison of Efficacy and Safety of Microfracture and Modified Microfracture
NCT02539030
UNKNOWN
PHASE4
Autologous Cell-derived Tissue Engineered Cartilage for Repairing Articular Cartilage Lesions
NCT02770209
UNKNOWN
NA
Biomaterials and Mesenchymal Stem/Stromal Cells in the Treatment of Knee Articular Surface Lesions
NCT06078072
COMPLETED
the Efficacy and Safety of a Modified Microfracture Using Collagen Compared to Those of a Simple Microfracture in Ankle
NCT02519881
UNKNOWN
PHASE4
Hydrolyzed Collagen and Undenatured Collagen Type II in OA Knee
NCT06229951
COMPLETED
NA
Allograft Transplantation in the Treatment of Osteoarthritis of the Metatarsophalangeal (MTP) Joint of the Great Toe
NCT01673347
COMPLETED
PHASE3
A Comparative Prospective Study of the Arthroscopic Meniscal Repair Methods
NCT06176183
RECRUITING
NA
Effectiveness of Hydrolyzed Collagen Peptide Injection for the Treatment of Collateral Ligament Pain
NCT05971004
COMPLETED
NA
ACL Reconstruction With Shark Screw® or Biocomposite-interference Screws
NCT06357091
RECRUITING
NA
Clinical Evaluation of a Resorbable PLLA Implant for Regeneration of the Anterior Cruciate Ligament (ACL)
NCT01634711
COMPLETED
PHASE1/PHASE2
Microfracture With/Without Collagen Augmentation in Patients Undergoing High Tibial Osteotomy
NCT02685917
UNKNOWN
NA
Augmentation of Anterior Cruciate Ligament Reconstruction Using Mesenchymal Stem Cells and Collagen Matrix Carrier
NCT05582226
UNKNOWN
NA
MAKO-Uni-Knee Arthroplasty Clinical Outcomes and Function
NCT03354195
COMPLETED
NA
Partial Meniscal Replacement with Spongioflex®
NCT06775197
RECRUITING
PHASE4
Survivorship and Outcomes of Robotic-Arm Assisted Medial Unicompartmental Knee Arthroplasty
NCT03668717
ACTIVE_NOT_RECRUITING
Early Outcomes of MAKO Medial Unicompartmental Knee Arthroplasty
NCT05736601
ACTIVE_NOT_RECRUITING
Does Addition of a Functional Knee Brace Improve Rehabilitation Outcome in Subjects With Osteoarthritis of the Knee?
NCT02712710
COMPLETED
NA
A Biologic Joint Replacement Strategy for Knee Trauma and Post-Traumatic Osteoarthritis
NCT03719417
COMPLETED
NA
Indications for Osteochondral Allograft Transplantation
NCT03711747
COMPLETED